(3.238.235.155) 您好!臺灣時間:2021/05/16 18:10
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:張允中
研究生(外文):Yeun-Chung Chang
論文名稱:以動態對比顯影磁振造影進行乳癌血管新生性之研究
論文名稱(外文):Study of Breast Cancer Angiogenesis UsingDynamic Contrast Enhanced MRI
指導教授:陳志宏陳志宏引用關係曾文毅曾文毅引用關係
學位類別:博士
校院名稱:國立臺灣大學
系所名稱:電機工程學研究所
學門:工程學門
學類:電資工程學類
論文種類:學術論文
論文出版年:2004
畢業學年度:92
語文別:英文
論文頁數:81
中文關鍵詞:血管新生性腫瘤反應磁振造影乳房
外文關鍵詞:magnetic resonancebreastMRangiogenesistumor response
相關次數:
  • 被引用被引用:0
  • 點閱點閱:183
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
動態對比顯影磁振造影為利用快速掃描,獲得組織接受顯影劑灌流時之系列影像,藉此可以反應組織血液灌流之狀況,亦可經由對比劑顯影程度而觀察到腫瘤血管特性。動態對比顯影磁振造影為非侵襲性腫瘤血管新生性的評估方式,藉由藥物動力學模式之應用,可反應腫瘤之血管新生性特徵及滲漏度,無外科或經皮切片只能獲得小體積標本的限制。我們使用以像素為基礎獲得之整體乳房彩色參數圖示,可以提供整體乳房組織與病灶具有血管新生性特點分布之評估。
在本論文中,我們使用新方法評估乳癌之整體血管新生特性,針對由二隔間模式衍算之磁振造影參數進行乳房病灶整體之組織圖分析。我們的研究結果顯示在良性惡性乳房病灶及腫瘤間,包括輻度、組織間交換速率及最大訊號顯影度,均存在明顯差異。使用此技術與評估方式,我們針對局部侵襲性乳癌的治療反應進行研究,結果顯示在化學治療前或在化學治療第一療程後施行顯影磁振造影檢查,可以藉由內在腫瘤磁振造影參數組成來預估術前化學治療之腫瘤反應。本研究亦發現化學治療有反應者之腫瘤,其血管新生性參數組成較常為不均質,而化學治療不反應之腫瘤,其血管新生性參數組成為較均質。在治療過程中,化學治療有反應者之腫瘤可由連續縱向磁振造影檢查中觀察到腫瘤變小,伴隨磁振造影血管新生參數組成也由不均質變為較均質。就我們所知,本研究為首先以動態對比顯影磁振造影研究乳癌內在組成在化學治療過程中變化的情況。
  本論文顯示使用動態顯影乳房磁振造影以磁振造影參數組織圖分析來評估腫瘤血管新生性,具有能夠提供腫瘤整體異質性之評估與內在組成血管新生性特徵之優點。未來研究方向應針對磁振造影腫瘤影像分析平台之研發,及發展相關標的磁振造影顯影劑,來探討功能性磁振造影,並結合腫瘤磁振造影分子影像之研究。
Dynamic contrast enhanced (DCE) MRI acquires sequential images during contrast perfusion of tissue of interest. Gadolinium chelates enable visualization of tumor vasculature through the degree of contrast enhancement, which reflects angiogenic properties and permeability of tumor. DCE MRI provides a window of noninvasive assessment of tumor angiogenesis without the limitation of small size of surgical specimen or percutaneous tumor sampling. Pixel-by-pixel high-resolution parametric color mapping of the whole breast provides good spatial assessment of angiogenic characters of breast lesions. We used a new approach for assessing global angiogenic character of breast cancer with quantitative analysis of MR parametric histogram obtained from compartmental model. With this analysis of MR parametric histogram, we demonstrated that there existed significant differences of parametric amplitude, compartmental exchange rate kout and maximal signal enhancement between benign and malignant breast lesions. Using this technique, tumor response of locally advanced breast cancer (LABC) may be predicted from the results of MR parametric histograms in the initial study before neoadjuvant chemotherapy or the study after the first course of neoadjuvant chemotherapy. Heterogeneity of internal parametric tumor composition was more commonly observed in responders. In contrast, tumor composition of nonresponders was more homogeneous. Involution of heterogeneous to more homogeneous tumor parametric composition was found in responders associated with reduction of tumor size in longitudinal MR studies. To our knowledge, this is the first report about the internal composition change of breast cancer on DCE MRI.
Our results suggest that MR parametric histogram analysis may assess global tumor angiogenesis and tumor heterogeneity. Further development of analytic platform of MR-based tumor imaging with perfusion model and clinically relevant targeted MR contrast agents may explore the capability of functional and molecular imaging in the near future.
1. An overview of breast MRI 8
1.1 History of breast MRI 8
1.2 Dynamic contrast enhanced (DCE) breast MRI 13
1.3 Interpretation of breast MRI 18
1.4 Pharmacokinetic models of DCE MRI analysis 23
1.5 Outline 28
2. MR parametric histogram and color mapping for benign and malignant tumors 29
2.1 Rationale of parametric analysis of DCE MRI based on two-compartment model 29
2.2 Materials and methods 32
2.3 Results 36
2.4 Discussion 41
3. MR angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy 47
3.1 Introduction 47
3.2 Materials and methods 49
3.3 Results 53
3.4 Discussion 54
4. Discussion and conclusion 61
4.1 Summary 61
4.2 Tumor segmentation using independent component analysis: work in progress 64
4.3 DCE MRI on tumor imaging and link with targeted MR imaging 68
4.4 Future work 69
Bibliography 70
1.Abraham DC, Jones RC, Jones SE, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996;78: 91-100.
2.Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988; 15;297(6654):943-948.
3.Ando Y, Fukatsu H, Ishiguichi T, et al. Diagnostic utility of tumor vascularity on magnetic resonance imaging of the breast. Magn Reson Imag 2000;18:807-813.
4.Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-e/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003;49:403-408.
5.Axelsson K, Liung BM, Moore DH, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Nath Cancer Inst 1995;87:997-1008.
6.Bjurstam N, Bjorneld L, Duffy SW, et al. The Gothenburg Breast Cancer Screening Trial: preliminary results on breast cancer mortality for women aged 39-49. J Natl Cancer Inst Monogr 1997;22:53-55.
7.Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspious breast lesions with a gadolinium-enhanced turbo flash subtraction technique. Radiology 1994;193:777-781.
8.Boetes C, Mus R, Holland R, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstration of extent. Radiology 1995;197:743-747.
9.Brix G, Semmler W, Port R, et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-628.
10.Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput. Assist Tomogr 1991;15:621-628.
11.Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200 639-647.
12.Buckley DL, Kerslake RW, Blackband SJ, Horsman A. Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR imaging using an automated simplex minimization procedure. Magn Reson Med 1994;32:646-651.
13.Buckley DL, Kerslake RW, Blackband SJ, Horsman A. Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR images using an automated simplex minimization procedure. Magn Reson Med 1994;32:646-651.
14.Buckley DL, Mussurakis S, Horseman A. Effect of temporal resolution on the diagnostic efficacy of contrast-enhanced MRI in the conservatively treated breast. J Comput Assist Tomogr 1998;22:47-51.
15.Carriero A, Ambrossini R, Mattei PA, Angelucci D, Bonoma L. Magnetic resonance of the breast: correlation between enhancement patterns and microvessel density in malignant tumors. J Exp Clin Cancer Res 2002; 21(S3):83-87.
16.Chang CW, Wang YM, Chang FH, Weng JC, Hsu YW, Chen JH. A new specific enzymatic contrast agent for magnetic resonance imaging. The third annual meeting of the society of molecular imaging. St. Louis, MO, USA, September 9-12, 2004.
17.Chang YC, Huang CS, Liu YJ, Chen JH, Lu YS, Tseng WY. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI. Phys Med Biol 2004, accepted.
18.Chen JH, Weng JC, Su HY, Chang CW, Chang FH. The RGD peptide-conjugated containing gadolinium DTPA for tumor imaging. The third annual meeting of the society of molecular imaging. St. Louis, MO, USA, September 9-12, 2004.
19.Chie WC, Chang SH, Huang CS, et al. Prognostic factors for the survival of Taiwanese breast cancer patients. J Formos Med Assoc 2002;101:98-103.
20.Chie WC, Chen SY, Chang KJ. Disability-adjusted Life Years of Breast Cancer in Taiwan. J Formos Med Assoc 2001;100:20-25.
21.Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer endocrine-related. Cancer 2002;9:183-195.
22.Crystal P, Strano SD, Shcharynski S, Koretz MJ. Using sonography to screen women with mammographically dense breasts. AJR Am J Roentgenol 2003;181:177-182.
23.Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998; 171:941–949.
24.Dash N, Lupetin AR, Daffner RH, et al. Magnetic resonance imaging in the diagnosis of breast disease. Am J Roentgenol 1986;146:119-125.
25.Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging- pilot study. Radiology 2003;228: 63-69.
26.Dennie J, Mandeville JB, Boxerman JL, et al. NMR imaging in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-799.
27.El Yousef SJ, Duchesneau RH. Magnetic resonance imaging of the human breast: a phase I trial. Radiol Clin North Am 1984;22:859-868.
28.El Yousel SJ, Duchesneau RH, Alfidi RJ, Haaga JR, Bryan PJ, LiPuma JP. Magnetic resonance imaging of the breast. Radiology 1984;150:761-766.
29.Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997;349:849.
30.Eltahir A, Heys SD, Hutcheon AW, et al. Treatment of large and locally advanced breast cancer using neoadjuvant chemotherapy. Am J Surg 1998;175:127-132.
31.Fischer U, Brinck U, Korabiowaska M, et al. The prognostic value of contrast-enhanced dynamic MR mammography in breast cancer. Euro Radiol 1997;7:1002-1005.
32.Fischer U, Kopla L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999;213:881-888.
33.Fobben ES, Rubin CZ, Kalisher L, et al. Breast MR imaging with commercially available techniques. Radiologic-pathologic correlation. Radiology 1995;196:143-152.
34.Folkman J. What is the evidence that tumors are angiogenesis dependent. J Natl Cancer Inst 1990;82:4-6.
35.Friedrich M 1997 Friedrich M Magnetic resonance imaging of the breast. In Friedrich M and Sickles EA (Eds). Radiological diagnosis of breast disease. Springer-Verlag, Berlin Heidelberg New York, 1997, p229-281.
36.Friedrich M. MRI of the breast: state of the art. Eur Radiol 1998;8:707-725.
37.Frouge C, Guinebretiere JM, Contresson G, Paola RD, Blery M. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest Radiol 1994;29:1043-1049.
38.Gilles R, Guinebretiere JM, Lucidarme O, et al. Nonpalpable breast tumors. Diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 1994;191:625-631.
39.Gilles R, Guinebretière JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994;191:633-638.
40.Hachiya J, Seki T, Okada M. MR imaging of the breast with Gd-DTPA enhancement: comparison with mammography and ultrasonography. Radiat Med 1991;9:232-240.
41.Harms SE, Flamig DP, Evans WP, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993;187:493-501.
42.Harms SE, Flamig DP, Hesley KL, et al. Fat-suppressed three-dimensional MR imaging of the breast. Radiographics 1993;13:247-267.
43.Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993;187:493-501.
44.Harms SE, Flaming DP. MR imaging of the breast. J Magn Res Imag 1993;3:277-283.
45.Hayes DF. Angiogenesis and breast cancer. Hematol Oncol Clin North Am 1994;8:51-71.
46.Heimann R, Ferguson D, Power C, et al. Angiogenesis as a predictor of long-term survival for patients with nod-negative breast cancer. J Natl Cancer Inst 1996;88:1764-1769.
47.Hendersn E, Rutt BK, Lee TY. Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imag 1998;16:1057-1073.
48.Heys S D, Eremin J M, Sarkar TK, Hutcheon AW, Ah-See A, Eremin O. Role of multimodality therapy in the management of locally advanced carcinoma of the breast. J Am Coll Surg 1994; 179:493-504.
49.Heywang SH, Fenzl G, Hahn D, et al. MRI of the breast: histopaghological considerations. Eur J Radiol 1987;493-501.
50.Heywang SH, Hahn D, Schmid, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986;10:199-204.
51.Heywang SH, Wolf A, Pruss E, et al. MR imaging of the breast with Gd-DTPA. Use and limitations. Radiology 1989;171:95-103.
52.Heywang-Köbrunner SH, Viehweg P, Heinig A, Kuchler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Euro J Radiol 1997;24:94-108.
53.Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ. Pharmacokinteic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 1995;33:506-514.
54.Hulka CA, Edmister WB, Smith BL, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997; 205:837-842.
55.Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995;197:33-38.
56.Hyvarinen A, Karhunen J, Oja E. Independent Component Analysis. New York: John Wiley & Sons; 2001.
57.Jackson VP, Hendrick RE, Feig SA, et al. Imaging of the radiographically dense breast. Radiology 1993;188:297-301.
58.Jensen JH, Chandra R. MR imaging of microvasculature. Magn Reson Med 2000;44:224-230.
59.Kaiser WA, Kess H. Prototype-doppelspule fur die Mamma-MR-Messung. Fortschr Rontgenstr 1989;151:103-105.
60.Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Radiology1989;170:681-686.
61.Kaiser WA. Dynamic magnetic resonance imaging using a double breast coil: an important routine examination of the breast front. Eur Radiol 1990;7:39-68.
62.Kao YH, Guo WY, Wu YT, et al. Hemodynamic segmentation of MR brain perfusion images using independent component analysis, thresholding, and Bayesian estimation. Magn Reson Med 2003;49:885-894.
63.Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, Choyke P. Dynamic contrast-enhanced magnetic resonance imaging. Topics in Magnetic Resonance Imaging 2001;12(4):301-308.
64.Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imag 1999;10:260-266.
65.Koning C, Hart G. Long-term follow-up of a randomized trial on adjuvant chemotherapy and hormonal therapy in locally advanced breast cancer. Int J Radiation Oncology Biol Phys 1998;41:397-400.
66.Kopans DB, Halpern E, Hulka CA. Statistical power in breast cancer screening trials and mortality reduction among women 40-49 years of age with particular emphasis on the National Breast Screening Study of Canada. Cancer 1994;15;74(4):1196-203.
67.Kopans DB. Preoperative imaging-guided needle placement and localization of clinically occult lesions. In Kopans DB (eds). Breast imaging. Philadelphia, JB Lippincott, 1989, pp 320-342.
68.Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999;211:101-110.
69.Lewis Jones HG, Whitehouse GH, Leinster SJ. The role of MRI in the assessment of local recurrent breast carcinoma. Clin Radiol 1991;43:19.
70.Liu PF, Debatin JF, Caduff RF, Kacl G, Garzoli E, Krestin GP. Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. Br J Radiol 1998;71(845):501-509.
71.Liu YJ, Huang IJ, Chung HW. The effect of sampling rate and total acquisition time for quantitative contrast-enhanced dynamic MR imaging. Proceedings in International Society of Magnetic Resonance in Medicine 2002, 10th Annual Meeting, #1908, Honolulu, U.S.A.
72.Mansfield P, Morris PG, Ordidge R. Carcinoma of the breast images by NMR. Br J Radiol 1979;52:242-243.
73.Merchant TE, Thelissen GRP, Kievit HCE, et al. Breast disease evaluation with fat-suppressed magnetic resonance imaging. Magn Reson Imaging 1992;10:335-340.
74.Mitchell D, Schnall, Sloan Rosten, et al A combined architectural and kinetic interpretation model for breast MR Images. Acad Radiol 2001; 8:591–597.
75.Mumtaz H, Hall-Craggs M, Davidson T, et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 1997;169:417-424.
76.Mussurakis S, Buckley DL, Drew PJ, et al. Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumors. Clin Radiol 1997;52:516-526.
77.Nunes LW. Architectural-based interpretations of breast MR imaging. MRI Clin Nor Am 2001:9:302-320.
78.Ochs MF, Stoyanova RS, Aris-Mendoza F, Brown TR. A new method for spectral decomposition using a bilinear Bayesian approach. J Magn Reson 1999;137:161–176.
79.Orel G. Differentiating benign from malignant enhancing lesions identified at MR imaging of the breast: are time intensity curves an accurate predictor? Radiology 1999;211:5-7.
80.Orel SG, Schnall MD, LiVolsi VA, et al. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994;190:485-493.
81.Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR guided biopsy 1995:196:115-122.
82.Ottinetti A, Sapino A. Morphometric evaluation of microvessels surrounding hyperplastic and neoplastic mammary lesions. Breast Cancer Res Treat 1988;11:241-248.
83.Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001;56 607-620.
84.Padhani AR. Dynamic contgrast-enhanced MRI studies in human tumours. Br J Radiol 1999;72:427-431.
85.Pamilo M, Soiva M, Anttinen I, et al. Ultrasonography of breast lesions detected in mammography screening. Acta Radiol 1991;32:220.
86.Pierce L, Adler D, Helvie M, Lichter A, Merajver S. The use of mammography in breast preservation in locally advanced breast cancer. Int J Radiation Oncology Biol Phys 1996;34 571-577.
87.Potterton AJ, Peakman DJ, Young JR. Ultrasound demonstration of small breast cancers detected by mammographic screening. Clin Radiol 1994;49:808.
88.Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 2002;12:1711-1719.
89.Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 1997;70:452-458.
90.Ries LAG, Kosary CKL, Hankey BF, et al. SEER Cancer Statistics Review 1973-1996. Nat Cancer Inst, Bethesda, MD USA, 1999.
91.Rodenko GN, Harms SE, Pruneda JM, et al. MR imaging in the management before surgery of lobular carcinoma of the breast: correlation with pathology. Am J Roentgenol 1996;167:1415-1419.
92.Ross RJ, Thompson JS, Kim K, et al: Nuclear magnetic resonance imaging and evaluation of human breast tissue: preliminary clinical trials. Radiology 1982;143:195-205.
93.Schwickert HC, Stiskal M, Roberts TP, et al. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 1996; 198:893–898.
94.Shieh DB, Yeh CL, Weng JC, et al. Anti-Her-2 monoclonal antibody conjugated non-polymer coated iron oxide nanoparticle as dual purpose contrast agent for targeted anti-cancer therapy and MR imaging. The third annual meeting of the society of molecular imaging. St. Louis, MO, USA, September 9-12, 2004.
95.Sondik EJ. Breast cancer trends: Incidence, mortality and survival. Cancer 1994; 74: 995-999.
96.Stack JP, Redmond V, Codd MB, et al. Breast disease: tissue characterization with Gd-DTPA-enhancement profiles. Radiology 1990;174:491-494.
97.Stomper PR, Herman S, Klippenstein, et al. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology 1995;197:387-395.
98.Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361(9367):1405-1410.
99.Taylor JS, Tofts PS, Phil D, et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imag 1999; 10:903-907.
100.Tofts P, Kermode A. Measurement of the blood-brain barrier and leakage space using dynamic MR imaging 1. fundamental concepts. Magn Reson in Med 1991;17:357-367.
101.Tofts PS, Berkowitz B, Schnall M. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995;33: 564-568.
102.Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imag 1999;10:223-232.
103.Tozer GM, Lewis S, Michalowski A, Aber V. The relationship between regional variations in blood flow and histology in a transplanted rat fibroadenoma. Br J cancer 1990;61:250-257.
104.Tuncblilek N, Unlu E, Karakas HM, Cakir B, Ozyilmaz F. Evaluation of tumor angiogenesis with contrast-enhanced dynamic magnetic resonance mammography. Breast J 2003;9:403-408.
105.Vinnicombe S, MarVocar AD, Guy RL, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy with pathologic correlation. Radiology 1996;198: 333-340.
106.Wasser K, Klein SK, Fink C, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MR with high spatial temporal resolution. Eur Radiol 2003; 13:80-87.
107.Wasser, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003;13:1213-1223.
108.Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with X-ray mammography and palpation. J Magn Reson Imag 2001; 13: 868-875.
109.Wedegartner U, Bick U, Wortler K, Rummeny E, Bongartz G. Differentiation between benign and malignant findings on MR-mammography: usefulness of morphological criteria. Eur Radiol 2001;11(9):1645-1650.
110.Weidner N and Folkman J. Tumoral vascularity as a prognostic factor in cancer In: DeVita VT, Hellman S, Rosenburg SA, eds. Important Advances in Oncology 1996. Philadelphia: Lippincott-Raven, 1996:167-190.
111.Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1886.
112.Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis- correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
113.Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis- correlation in invasive breast cancer. N Engl J Med 1991;324: 1-8.
114.Weidner N. Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:1029-39.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文
 
1. 36.王冠堯,烘焙餡料與市場流行,食品資訊雜誌社第173期,網址- http://www.foodnews.com.tw/market-185.html#point2
2. 林尚平、陳怡安(2001)。遊樂區員工情緒勞務及社會化歷程之質性研究。商管科技季刊,2,3,319-343。
3. 11.黃俊英、賴文彬,「涉入的理論發展與實務應用」,管理科學學報,第七卷第一期,民國79 年5 月
4. 陳以亨、楊乃嵩、林瑩滋(2001)。指導教授領導行為與研究生學業成就動機之關係。人力資源管理學報,1,2,113-132。
5. 許道然(2002)。組織公民行為之研究。空大行政學報,12,113-146。
6. 施能傑(1992)。考績謬誤的類型與原因:理論闡述與經驗分析(上、下)。人事月刊,14,(3、4)。
7. 林尚平、張淑慧(1998)。情緒勞務與組織人力發展之關係。人力發展月刊,48,43-52。
8. 林鉦棽(2003)。製造業從業人員之社會交換變數在組織公正與工作滿意對組織公民行為關係中的中介角色分析—以多重評量來源之研究設計觀點。中原企管評論,1,1,81-110。
9. 林鉦棽(2004)。「休閒旅館業從業人員的組織公正、組織信任、組織公民行為關係:社會交換理論之觀點,中華管理學報,5,3,91-112。
10. 林鉦棽、蔡明慶(2003)。社會交換系統與組織控制系統對組織公民行為之影響,亞太社會科技學報,3,1,1-25。
11. 林鉦棽(1996)。組織公正、信任、組織公民行為之研究:社會交換交換理論之觀點,管理科學學報,13,391-416。
12. 吳雅玲(1998)。淺談印象整飾理論及其在教育上之應用。教育實習輔導, 3, 12, 75-79。